Introduction: Chronic coronary disease (CCD) commonly coexists with long-term oral anticoagulation (OAC), particularly for atrial fibrillation (AF). Combination antiplatelet therapy increases bleeding, whereas ischemic protection with OAC alone remains a concern. We critically appraised contemporary evidence and guidelines to define optimal long-term maintenance therapy.Methods: We synthesized WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, AFIRE, OAC-ALONE, PRAEDO-AF,… Continue reading Antithrombotic Therapy in Patients with Chronic Coronary Disease on Anticoagulation: Evidence from Contemporary Trials
Tag: AMI
Is Ferroptosis and Oxidative Stress Involved in NSTEMI Patient’s?
Highlights: Ferroptosis (iron-dependent lipid peroxidation-driven cell death) is implicated in ischemic injury.NSTEMI patients showed significantly higher oxidative stress (↑LPO) and iron overload (↑iron, ↑ferritin) vs controls.Antioxidant defenses were reduced in NSTEMI (↓TAC, ↓TTG, ↓SOD, ↓GPx activity).This biomarker pattern supports ferroptosis activation contributing to myocardial injury in NSTEMI.Background: Ischemic heart disease is the leading cause of… Continue reading Is Ferroptosis and Oxidative Stress Involved in NSTEMI Patient’s?
Ultrashort vs Standard-Duration Dual Antiplatelet Therapy in Acute Coronary Syndrome Patients Undergoing PCI: A Meta-Analysis
Background: The efficacy and safety of ultrashort (≤1-month) dual antiplatelet therapy (DAPT) followed by antiplatelet monotherapy remain uncertain in acute coronary syndrome (ACS) patients.Objectives: This study sought to compare ultrashort vs standard-duration DAPT in patients with ACS undergoing percutaneous coronary intervention (PCI).Methods: We conducted a systematic review and meta-analysis of randomized controlled trials until February… Continue reading Ultrashort vs Standard-Duration Dual Antiplatelet Therapy in Acute Coronary Syndrome Patients Undergoing PCI: A Meta-Analysis
Differential Prognostic Impact of Potent P2Y₁₂ Inhibitors in Patients With Acute Myocardial Infarction by Bleeding Risk
Background and objectives: Limited data on the comparative efficacy and safety of potent P2Y₁₂ inhibitors versus clopidogrel in patients with acute myocardial infarction (AMI) stratified by bleeding risk. This study evaluated the differential prognostic impact of potent P2Y₁₂ inhibitors in patients with AMI by bleeding risk.Methods: From the nationwide pooled registry of the Korea Acute… Continue reading Differential Prognostic Impact of Potent P2Y₁₂ Inhibitors in Patients With Acute Myocardial Infarction by Bleeding Risk
Impact of β-blocker therapy after acute myocardial infarction in patients with preserved ejection fraction: a meta-analysis
Introduction: Despite earlier evidence, the benefit of long-term #β-blockers after myocardial infarction (MI) in patients with preserved or mildly reduced ejection fraction remains unclear in the modern reperfusion era.Methods: We conducted a PRISMA-guided systematic review and meta-analysis by searching the PubMed, Google Scholar, and Cochrane databases, pooling results using a random effects model with 95%… Continue reading Impact of β-blocker therapy after acute myocardial infarction in patients with preserved ejection fraction: a meta-analysis
Prior Myocardial Infarction and Cognitive Decline: The REGARDS Cohort
Background: Acute myocardial infarction (#MI ) is associated with subsequent #cognitive decline. Whether the detection of prior MI using routine ECG and self-reported history can identify different trajectories of cognitive decline is uncertain. We sought to determine the association between prior MI and longitudinal cognitive assessments within a national, biracial cohort study.Methods: We included participants… Continue reading Prior Myocardial Infarction and Cognitive Decline: The REGARDS Cohort
Evaluation of Rabeprazole for Gastrointestinal Protection in Acute Coronary Syndrome Patients Treated with Aspirin and Ticagrelor: A Pilot Study
Purpose: Patients with acute coronary syndrome (#ACS ) on ticagrelor-based dual antiplatelet therapy (#DAPT ) have an increased risk of gastrointestinal (GI) bleeding. However, evidence supporting the protective role of proton pump inhibitors against DAPT-induced gastric mucosal injury remains limited.Materials and methods: This was a single-center, prospective, open-label, observational trial enrolling patients with ACS who… Continue reading Evaluation of Rabeprazole for Gastrointestinal Protection in Acute Coronary Syndrome Patients Treated with Aspirin and Ticagrelor: A Pilot Study
Electroacupuncture for slow flow/no-reflow in patients with acute myocardial infarction undergoing percutaneous coronary intervention: a pilot randomized controlled trial
Background: Slow flow/no-reflow (SF-NR) complicates up to 44% of percutaneous #coronary interventions ( #PCI) for acute myocardial infarction (#AMI), worsening prognosis. Electroacupuncture (EA) may mitigate SF-NR, but clinical evidence is limited.Objective: This trial was designed to assess the feasibility and effectiveness of intraoperative EA in reducing SF-NR during PCI for AMI patients.Design setting and participants… Continue reading Electroacupuncture for slow flow/no-reflow in patients with acute myocardial infarction undergoing percutaneous coronary intervention: a pilot randomized controlled trial
#Beta-blockers after myocardial #infarction: effects according to #sex in the REBOOT trial
Background and AimsRecent trials have challenged the guideline recommendation of beta-blockers for post-myocardial infarction (MI) patients without reduced left ventricular ejection fraction (LVEF). Whether these recent findings apply equally to women and men remains unknown.MethodsUsing data from REBOOT (tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion), the largest randomized trial evaluating the effect… Continue reading #Beta-blockers after myocardial #infarction: effects according to #sex in the REBOOT trial
